

Claudia Cocco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7238341/publications.pdf>

Version: 2024-02-01

35
papers

1,395
citations

279701

23
h-index

414303

32
g-index

35
all docs

35
docs citations

35
times ranked

2097
citing authors

#	ARTICLE	IF	CITATIONS
1	Î³Î± T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCRÎ±Î²+/CD19+ lymphocytes. <i>Blood</i> , 2015, 125, 2349-2358.	0.6	224
2	Lack of IL12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. <i>Blood</i> , 2005, 106, 3846-3853.	0.6	110
3	Interleukin-27 Acts as Multifunctional Antitumor Agent in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2010, 16, 4188-4197.	3.2	88
4	Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3996-4001.	3.3	83
5	Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. <i>Cell Research</i> , 2011, 21, 1470-1486.	5.7	66
6	Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. <i>Leukemia</i> , 2011, 25, 1815-1824.	3.3	59
7	The IL-12RÎ²2 gene functions as a tumor suppressor in human B cell malignancies. <i>Journal of Clinical Investigation</i> , 2004, 113, 1651-1659.	3.9	52
8	CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 541-548.	2.0	50
9	Interleukin-27 Inhibits the Growth of Pediatric Acute Myeloid Leukemia in NOD/SCID/Î²2m ^{-/-} Mice. <i>Clinical Cancer Research</i> , 2012, 18, 1630-1640.	3.2	50
10	Immunogenicity of Human Neuroblastoma. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 69-80.	1.8	48
11	Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. <i>Leukemia</i> , 2012, 26, 1365-1374.	3.3	48
12	CXCL12 Does Not Attract CXCR4+ Human Metastatic Neuroblastoma Cells: Clinical Implications. <i>Clinical Cancer Research</i> , 2006, 12, 77-82.	3.2	47
13	Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. <i>Blood</i> , 2010, 116, 3887-3898.	0.6	46
14	IL-12 Can Target Human Lung Adenocarcinoma Cells and Normal Bronchial Epithelial Cells Surrounding Tumor Lesions. <i>PLoS ONE</i> , 2009, 4, e6119.	1.1	43
15	Interleukin-27 and interleukin-23 modulate human plasmacell functions. <i>Journal of Leukocyte Biology</i> , 2011, 89, 729-734.	1.5	40
16	Constitutive expression of IL-12RÎ²2 on human multiple myeloma cells delineates a novel therapeutic target. <i>Blood</i> , 2008, 112, 750-759.	0.6	38
17	Direct inhibition of human acute myeloid leukemia cell growth by IL-12. <i>Immunology Letters</i> , 2010, 133, 99-105.	1.1	34
18	Heterogeneous Expression of Interleukin-18 and Its Receptor in B-Cell Lymphoproliferative Disorders Deriving from Naive, Germinal Center, and Memory B Lymphocytes. <i>Clinical Cancer Research</i> , 2004, 10, 144-154.	3.2	32

#	ARTICLE	IF	CITATIONS
19	Interleukin-30 Promotes Breast Cancer Growth and Progression. <i>Cancer Research</i> , 2016, 76, 6218-6229.	0.4	32
20	Interleukin-12 Receptor $\beta 2$: From Cytokine Receptor to Gatekeeper Gene in Human B-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2009, 27, 4809-4816.	0.8	27
21	The IL-12 $\beta 2$ gene functions as a tumor suppressor in human B cell malignancies. <i>Journal of Clinical Investigation</i> , 2004, 113, 1651-1659.	3.9	27
22	Methylation of the IL-12 $\beta 2$ Gene as Novel Tumor Escape Mechanism for Pediatric B-Acute Lymphoblastic Leukemia Cells. <i>Cancer Research</i> , 2006, 66, 3978-3980.	0.4	26
23	Chemokines in neuroectodermal tumour progression and metastasis. <i>Seminars in Cancer Biology</i> , 2009, 19, 97-102.	4.3	26
24	New Perspectives for Melanoma Immunotherapy: Role of IL-12. <i>Current Molecular Medicine</i> , 2009, 9, 459-469.	0.6	20
25	Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia. <i>Oncotarget</i> , 2014, 5, 10368-10381.	0.8	18
26	Anti-leukemic properties of IL-12, IL-23 and IL-27: Differences and similarities in the control of pediatric B acute lymphoblastic leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 310-318.	2.0	16
27	Cytokines and microRNA in pediatric B-acute lymphoblastic leukemia. <i>Cytokine and Growth Factor Reviews</i> , 2011, 22, 149-156.	3.2	15
28	Targeting acute myeloid leukemia cells with cytokines. <i>Journal of Leukocyte Biology</i> , 2012, 92, 567-575.	1.5	12
29	Absence of IL-12 $\beta 2$ in CD33+CD38+ pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2R β -deficient mice. <i>Leukemia</i> , 2012, 26, 225-235.	3.3	7
30	IL-21: a new player in the control of isotype switch in Peyer's patches. <i>Journal of Leukocyte Biology</i> , 2009, 85, 739-743.	1.5	5
31	Cytokines as Anti-Angiogenic Agents in Haematological Malignancies. <i>Current Cancer Drug Targets</i> , 2011, 11, 997-1004.	0.8	3
32	Research Highlights: Highlights from the latest articles in immunomodulation. <i>Immunotherapy</i> , 2012, 4, 667-670.	1.0	2
33	Recovery Of Gamma/Delta+ T Cells After Transplantation With Alpha-Beta+/CD19+ Lymphocyte Depleted Hematopoietic Stem Cells From HLA-Haploidentical Donors. <i>Blood</i> , 2013, 122, 3245-3245.	0.6	1
34	IL-22 as key factor of thymic regeneration. <i>Immunotherapy</i> , 2012, 4, 668.	1.0	0
35	Graft-versus-host disease is ameliorated by blocking of IL-21 signaling. <i>Immunotherapy</i> , 2012, 4, 669-70.	1.0	0